Home » Ranbaxy Gets Tentative Nod for Galantamine
Ranbaxy Gets Tentative Nod for Galantamine
Ranbaxy Laboratories Ltd receives tentative approval from U.S. Food and Drug Administration to manufacture and market Galantamine Hydrobromide Tablets, 4, 8 and 12 mg (base). Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
India Infoline
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May